[Metastatic breast cancer--new methods of treatment]

MeSH terms

• Angiogenesis Inhibitors / administration & dosage
• Angiogenesis Inhibitors / pharmacology
• Angiogenesis Inhibitors / therapeutic use*
• Antibodies, Monoclonal / administration & dosage
• Antibodies, Monoclonal / adverse effects
• Antibodies, Monoclonal / pharmacology
• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects
• Antineoplastic Agents / pharmacology
• Antineoplastic Agents / therapeutic use*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Bevacizumab
• Bone Density Conservation Agents / administration & dosage
• Bone Density Conservation Agents / adverse effects
• Bone Density Conservation Agents / pharmacology
• Bone Density Conservation Agents / therapeutic use*
• Bone Neoplasms / prevention & control
• Bone Neoplasms / secondary
• Breast Neoplasms / diagnosis
• Breast Neoplasms / drug therapy*
• Breast Neoplasms / mortality
• Clinical Trials, Phase III as Topic
• Diphosphonates / administration & dosage
• Diphosphonates / adverse effects
• Diphosphonates / pharmacology
• Diphosphonates / therapeutic use*
• Female
• Histocytochemistry
• Humans
• Lapatinib
• Neoplasm Metastasis
• Osteonecrosis / chemically induced
• Protein Kinase Inhibitors / administration & dosage
• Protein Kinase Inhibitors / pharmacology
• Protein Kinase Inhibitors / therapeutic use*
• Quinazolines / administration & dosage
• Quinazolines / pharmacology
• Quinazolines / therapeutic use*
• Receptor, ErbB-2 / drug effects
• Risk Factors
• Signal Transduction / drug effects
• Time Factors
• Trastuzumab